Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings

Annals of Hematology

Volumn 94, Issue 10, 2015, Pages 1677-1688

  Tischer, Johanna ^a   Engel, Nicole ^a   Fritsch, Susanne ^a   Prevalsek, Dusan ^a   Hubmann, Max ^a   Schulz, Christoph ^a   Zoellner, Anna K ^a   Bücklein, Veit ^a   Reibke, Roland ^a   Mumm, Friederike ^a   Rieger, Christina T ^a   Hill, Wolfgang ^a   Ledderose, Georg ^a   Stemmler, Hans Joachim ^a   Köhnke, Thomas ^a   Jäger, Gundula ^b   Kolb, Hans Jochem ^c   Schmid, Christoph ^d   Moosmann, Andreas ^a,e   Hausmann, Andreas ^a,f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Klinikum Augsburg ^*  (Germany)

^d KLINIKUM AUGSBURG   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f Klinikum Schwabing   (Germany)

Author keywords

Herpes virus infection; High dose cyclophosphamide posttransplantation; HLA haploidentical hematopoietic stem cell transplantation; Immune reconstitution; T cell replete; Virus infection

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY; TREOSULFAN; HLA ANTIGEN;

ADENOVIRUS INFECTION; ADULT; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HLA HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFLUENZA A; MALE; MORTALITY; NATURAL KILLER CELL; PARVOVIRUS INFECTION; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; VIRUS INFECTION; VIRUS INFECTION RELATED MORTALITY; ADOLESCENT; ADVERSE EFFECTS; CONVALESCENCE; GRAFT VS HOST DISEASE; HAPLOTYPE; HERPESVIRIDAE INFECTIONS; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HLA ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84941026063     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2423-y     Document Type: Article

References (54)

1. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA (1990) Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29(2):79–91
2. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, Barrett A, Jameson B, Depledge MH, Watson JG, Sloane J, Leigh M, Lumley H, Hedley D, Lawler SD, Filshie J, Robinson B (1983) Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1(8325):612–615
3. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, Henslee PJ, Kolb HJ, Lowenberg B, Masaoka T et al (1991) Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 7(6):443–452
4. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339(17):1186–1193. doi:10.1056/NEJM199810223391702
5. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23(15):3447–3454. doi:10.1200/JCO.2005.09.117
6. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112(9):3574–3581. doi:10.1182/blood-2008-02-140095
7. Lacerda JF, Martins C, Carmo JA, Lourenco F, Juncal C, Rodrigues A, Vilalobos I, Moura MC, Ligeiro D, Martinho A, Lacerda JM (2003) Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. Biol Blood Marrow Transplant 9(10):633–642. doi:10.1016/S1083
8. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I (2006) Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12(10):1073–1084. doi:10.1016/j.bbmt.2006.06.007
9. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ (2007) Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25(6):690–697. doi:10.1200/JCO.2006.07.0953
10. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353(9166):1755–1759. doi:10.1016/S0140-6736(98)11135-2
11. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, Bader P, Schlegel PG, Greil J, Stachel D, Herzog RJ, Niethammer D (2001) Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27(8):777–783. doi:10.1038/sj.bmt.1702996
12. Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L (2006) Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 34(12):1746–1752. doi:10.1016/j.exphem.2006.08.009
13. Boeckh M, Erard V, Zerr D, Englund J (2005) Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant 9(Suppl 7):48–54. doi:10.1111/j.1399-3046.2005.00442.x
14. Dykewicz CA (2001) Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33(2):139–144. doi:10.1086/321805
15. Einsele H, Bertz H, Beyer J, Kiehl MG, Runde V, Kolb HJ, Holler E, Beck R, Schwerdfeger R, Schumacher U, Hebart H, Martin H, Kienast J, Ullmann AJ, Maschmeyer G, Kruger W, Niederwieser D, Link H, Schmidt CA, Oettle H, Klingebiel T (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S175–185. doi:10.1007/s00277-003-0772-4
16. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE (2012) Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1835–1844. doi:10.1016/j.bbmt.2012.07.003
17. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
18. Schuster FR, Meisel R, Fuhrer M, Reuther S, Hauer J, Tischer J, Feuchtinger T, Laws HJ, Kolb HJ, Borkhardt A (2013) Anti-leukaemic activity of a novel haploidentical-transplantation approach employing unmanipulated bone marrow followed by CD6-depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia. Br J Haematol 162(6):802–807. doi:10.1111/bjh.12455
19. Kolb H-J, Bigalke I, Simoes B, Falk C, Tischer J, Hill W, Ledderose G (2004) CD6-depleted mobilized stem cells for modification of HVG and GVH reactions after HLA-haploidentical marrow transplantation. ASH Annu Meet Abstr 104(11):978
20. Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, Zoellner AK, Bucklein V, Lippl S, Reibke R, Rieger CT, Ledderose G, Stemmler HJ, Hiddemann W, Schmid C, Hausmann A (2014) Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant 49(7):895–901. doi:10.1038/bmt.2014.83
21. Tischer J, Stemmler HJ, Engel N, Hubmann M, Fritsch S, Prevalsek D, Schulz C, Zoellner AK, Bucklein V, Hill W, Ledderose G, Hausmann A (2013) Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol 92(10):1379–1388. doi:10.1007/s00277-013-1862-6
22. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34(8):1094–1097. doi:10.1086/339329
23. Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, Maier M, Liebert UG, Niederwieser D, Engelmann E, Heilbronn R, Thiel E, Uharek L (2007) Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39(5):293–299. doi:10.1038/sj.bmt.1705585
24. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633. doi:10.1016/j.bbmt.2009.07.004
25. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956. doi:10.1016/j.bbmt.2005.09.004
26. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828
27. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
28. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115(14):2960–2970. doi:10.1182/blood-2009-08-236356
29. Mulanovich VE, Jiang Y, de Lima M, Shpall EJ, Champlin RE, Ciurea SO (2011) Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res 1(1):98–105
30. Parody R, Martino R, Rovira M, Vazquez L, Vazquez MJ, de la Camara R, Blazquez C, Fernandez-Aviles F, Carreras E, Salavert M, Jarque I, Martin C, Martinez F, Lopez J, Torres A, Sierra J, Sanz GF (2006) Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 12(7):734–748. doi:10.1016/j.bbmt.2006.03.007
31. Ruggeri A, Peffault de Latour R, Carmagnat M, Clave E, Douay C, Larghero J, Cayuela JM, Traineau R, Robin M, Madureira A, Ribaud P, Ferry C, Devergie A, Purtill D, Rabian C, Gluckman E, Toubert A, Socie G, Rocha V (2011) Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis 13(5):456–465. doi:10.1111/j.1399-3062.2011.00632.x
32. Verdeguer A, de Heredia CD, Gonzalez M, Martinez AM, Fernandez-Navarro JM, Perez-Hurtado JM, Badell I, Gomez P, Gonzalez ME, Munoz A, Diaz MA (2011) Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. Bone Marrow Transplant 46(1):119–124. doi:10.1038/bmt.2010.52
33. Chang YJ, Zhao XY, Huo MR, Xu LP, Liu DH, Liu KY, Huang XJ (2012) Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol 32(2):268–280. doi:10.1007/s10875-011-9630-7
34. Dominietto A, Raiola AM, Bruno B, van Lint MT, Frassoni F, Grazia CD, Gualandi F, Bregante S, Varaldo R, Ghiso A, Bacigalupo A (2011) Rapid immune reconstitution following unmanipulated haploidentical BMT with post-transplant high dose cyclophosphamide. ASH Annu Meet Abstr 118(21):3050
35. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065–3073. doi:10.1182/blood-2005-05-2146
36. Rieger CT, Rieger H, Kolb HJ, Peterson L, Huppmann S, Fiegl M, Ostermann H (2009) Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings. Transpl Infect Dis 11(3):220–226. doi:10.1111/j.1399-3062.2009.00379.x
37. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhauser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socie G, Group AT-FT (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864
38. Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C (2011) ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(8):1237–1244. doi:10.1016/j.bbmt.2010.12.705
39. Muller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, Lange H (1997) Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64(10):1432–1437
40. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins DR, Brown RA, DiPersio JF (1999) Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 23(4):335–346. doi:10.1038/sj.bmt.1701581
41. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ (2001) Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98(12):3456–3464
42. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A (2013) Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19(1):117–122. doi:10.1016/j.bbmt.2012.08.014
43. Mayumi H, Himeno K, Tokuda N, Nomoto K (1986) Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination. Transplant Proc 18(2):363–369
44. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L (2013) Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 5(211):211ra–157. doi:10.1126/scitranslmed.3006960
45. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75(10):1947–1950
46. Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ (2011) Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 3(Suppl 2):e15. doi:10.4081/pr.2011.s2.e15
47. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H, Bolanos-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 19(4):602–606. doi:10.1016/j.bbmt.2013.01.006
48. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A (2012) Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 18(12):1859–1866. doi:10.1016/j.bbmt.2012.06.019
49. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE (2006) Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8):2874–2880. doi:10.1182/blood-2006-03-011791
50. Berger M, Figari O, Bruno B, Raiola A, Dominietto A, Fiorone M, Podesta M, Tedone E, Pozzi S, Fagioli F, Madon E, Bacigalupo A (2008) Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 41(1):55–62. doi:10.1038/sj.bmt.1705870
51. 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 37(12):1119–1128. doi:10.1038/sj.bmt.1705381
52. Chang YJ, Zhao XY, Xu LP, Liu DH, Liu KY, Chen YH, Wang Y, Zhang XH, Zhao XS, Han W, Chen H, Wang FR, Lv M, Huang XJ (2013) Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. Leuk Lymphoma 54(12):2671–2677. doi:10.3109/10428194.2013.783912
53. Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE (2011) Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 17(8):1169–1175. doi:10.1016/j.bbmt.2010.11.020
54. Wolfromm A, Porcher R, Legoff J, Peffault de Latour R, Xhaard A, de Fontbrune FS, Ribaud P, Bergeron A, Socie G, Robin M (2014) Viral respiratory infections diagnosed by multiplex PCR after allogeneic hematopoietic stem cell transplantation: long-term incidence and outcome. Biol Blood Marrow Transplant 20(8):1238–1241. doi:10.1016/j.bbmt.2014.04.004